DURATION: 60 MIN
REGISTER NOW!
Hear expert panelists bring their perspectives on critical issues around support for Medicare Part D products’ fair market prices.
Centers for Medicare & Medicaid Services (CMS) will begin negotiating with manufacturers on the price of Medicare Part D drugs beginning this year. In September, CMS will publish the list of 10 Part D selected drugs for negotiations. A key issue in the negotiations will be determination of the fair market price for a product.
Key Topics:
- Outline how CMS might select the 10 products that will be required to negotiate their prices this fall
- Describe how CMS will determine fair market prices for Medicare Part D drugs
- Suggest actions that manufacturers could take in response to the Medicare Part D price negotiation requirements
Presenters:
Mark McCoy, RPh, MBA
Director, Client Engagement
Pricing, Market Access and Reimbursement
ICON
Earlene Biggs, PhD
Divisional Principal
Market Access
ICON
Bruce Capobianco, BS
Head of Business Intelligence
Commercial Solutions
ICON
Tamie Joeckel, BS
Global Business Lead
Cell and Gene Therapy
ICON
Tanja Obradovic, PhD
VP, Scientific Affairs
Oncology Medical Strategy
ICON
Ki Park, MBA
VP, PMAC Consulting
Patient Insight, Market Access and Commercial
ICON
Nancy Risebrough, BA
Senior Principal
Global Health Economics and Outcomes Research
ICON
